

LY6E Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP13818c**Specification**

LY6E Antibody (Center) Blocking peptide - Product InformationPrimary Accession [Q16553](#)**LY6E Antibody (Center) Blocking peptide - Additional Information****Gene ID** 4061**Other Names**

Lymphocyte antigen 6E, Ly-6E, Retinoic acid-induced gene E protein, RIG-E, Stem cell antigen 2, SCA-2, Thymic shared antigen 1, TSA-1, LY6E, RIGE, SCA2, TSA1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13818c was selected from the Center region of LY6E. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LY6E Antibody (Center) Blocking peptide - Protein Information**Name** LY6E ([HGNC:6727](#))**Synonyms** 9804, RIGE, SCA2, TSA1**Function**

GPI-anchored cell surface protein that regulates T- lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation (By similarity). Restricts the entry of human coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2, by interfering with spike protein-mediated membrane fusion (PubMed:32641482). Also plays an essential role in placenta formation by acting as the main receptor for syncytin-A (SynA). Therefore, participates in the normal fusion of syncytiotrophoblast layer I (SynT- I) and in the proper morphogenesis of both fetal and maternal vasculatures within the placenta. May also act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity (By similarity).

Cellular Location

Cell membrane {ECO:0000250|UniProtKB:Q64253}; Lipid-anchor, GPI-anchor
{ECO:0000250|UniProtKB:Q64253}

Tissue Location

Widely expressed, predominantly in liver, kidney, ovary, spleen and peripheral blood Leukocytes

LY6E Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

LY6E Antibody (Center) Blocking peptide - Images**LY6E Antibody (Center) Blocking peptide - Background**

Sca1, also known as Ly6A/E, is a member of the Ly6 multigene family of type V glycoposphatidylinositol anchored cell surface proteins. It is expressed on multipotent hematopoietic stem cells in bone marrow of mice with both the Ly6.1 and Ly6.2 allotypes. In the periphery, Sca1 exhibits a pattern of expression which is based on differences between the two allotypes. Ly6.1 strains (e.g., A, BALB/c, CBA, C3H/He, DBA/1, NZB) have few Sca1+ resting peripheral lymphocytes, whereas Ly6.2 strains (e.g., AKR, C57BL, C57BR, C57L, DBA/2, PL, SJL, SWR, 129) have relatively high numbers of Sca1+ lymphocytes. The expression of Sca1 is dramatically upregulated in all strains upon cellular activation.

LY6E Antibody (Center) Blocking peptide - References

Davila, S., et al. Genes Immun. 11(3):232-238(2010)Wang, J.L., et al. Mov. Disord. 24(13):2007-2011(2009)Socal, M.P., et al. Parkinsonism Relat. Disord. 15(5):374-378(2009)Tang, J., et al. Lupus 17(9):805-813(2008)Wang, A.G., et al. Biochem. Biophys. Res. Commun. 345(3):1022-1032(2006)